By Fineline Cube 
Daiichi Sankyo Co., Ltd. (TYO: 4568) and Innovent Biologics, Inc. (HKG: 1801) announced an exclusive entrusted promotion agreement for the commercialization of Vanflyta (Quizartinib Hydrochloride Tablets) in mainland China. Under the deal, Daiichi Sankyo retains responsibility for clinical development, manufacturing, and supply, while Innovent secures exclusive promotion rights and will lead all commercial efforts in the Chinese market. Financial terms were not disclosed.
Deal Snapshot
| Item | Detail |
|---|---|
| Companies | Daiichi Sankyo (TYO: 4568) & Innovent Biologics (HKG: 1801) |
| Agreement Type | Exclusive entrusted promotion |
| Product | Vanflyta (Quizartinib Hydrochloride Tablets) |
| Market | Mainland China |
| Daiichi Sankyo Role | Clinical development, manufacturing, supply |
| Innovent Role | Exclusive promotion rights; leads commercial efforts |
| Announcement Date | 10 Aug 2026 |
Drug Profile & Mechanism of Action
- Molecule: Oral, potent type II FLT3 inhibitor
- Target: FLT3‑ITD (FMS‑like tyrosine kinase 3 internal tandem duplication) mutation
- Innovation: Selective inhibition of the FLT3‑ITD mutation, which is present in roughly 25 % of adult AML cases; the type II binding mode distinguishes it from earlier FLT3 agents by stabilizing the inactive kinase conformation.
- Intellectual Property: Developed and supplied by Daiichi Sankyo; promotion rights licensed to Innovent in China.
Regulatory & Clinical Backdrop
| Item | Detail |
|---|---|
| Approval Agency | NMPA (China) |
| Approval Date | June 2026 |
| Indication | Adult patients with newly diagnosed AML who are FLT3‑ITD positive (confirmed by fully validated test) |
| Induction Phase | In combination with standard‑dose cytarabine + anthracyclines |
| Consolidation Phase | In combination with cytarabine |
| Maintenance Phase | Single‑agent therapy following consolidation |
The three‑phase positioning — spanning induction, consolidation, and maintenance — gives Vanflyta a broader treatment arc than many competitors limited to later‑line or maintenance‑only settings.
Market Impact & Outlook
- China AML Landscape: AML remains one of the most aggressive hematologic malignancies in China, with FLT3‑ITD mutations conferring poor prognosis. An oral targeted therapy integrated across all treatment phases addresses a significant unmet need.
- Revenue Forecast: Analysts estimate the China FLT3‑targeted therapy market could reach ¥3–4 billion (≈ US$420–560 million) annually by 2028, with Vanflyta positioned to capture a meaningful share given its full‑arc indication.
- Competitive Edge: Vanflyta’s approval across induction, consolidation, and maintenance phases differentiates it from agents restricted to relapse/refractory or post‑consolidation settings.
- Strategic Rationale: For Daiichi Sankyo, the partnership leverages Innovent’s established hematology commercial infrastructure and hospital relationships without the capital outlay of building a dedicated China sales force. For Innovent, the deal adds a revenue‑generating promoted asset amid a challenging funding environment for Chinese biotechs.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercial potential of Vanflyta in China and the anticipated benefits of the Daiichi Sankyo–Innovent partnership. Actual results may differ materially due to regulatory developments, competitive dynamics, reimbursement negotiations, and market acceptance. The companies have not disclosed revenue forecasts or deal economics. Investors should consult official filings for updated risk factors.-Fineline Info & Tech